National Health Act 1953 Determination under subsections 85A(1) and (2) and 88(1C) Prescription of pharmaceutical benefits by authorised Optometrists (No. PB 11 of 2009) (Cth)

Determination — Prescription of pharmaceutical benefits by authorised optometrists

(PB 11 of 2009)

as amended

made under subsections 85A (1) and (2) and 88(1C) of the

National Health Act 1953

This compilation was prepared on 1 November 2010
taking into account amendments up to PB 98 of 2010

Prepared by the Office of Legislative Drafting and Publishing,
Attorney‑General’s Department, Canberra

Determination — Prescription of pharmaceutical benefits by authorised

optometrists (PB 11 of 2009)

1          Commencement  [see Note 1]

This instrument commences on 1 March 2009.

2          Repeal

Instrument number PB 116 of 2008 is repealed.

3          Definition

In this instrument:

Act means the National Health Act 1953.

4          Form allowable

For subsection 85A(1) of the Act, the form of a pharmaceutical benefit mentioned in an item of Schedule 1 that is allowable for prescription by an authorised optometrist is the form mentioned in the description of the pharmaceutical benefit in the item.

Note    More than 1 form may have been determined for a pharmaceutical benefit , in which case each form is allowable for prescription: see Acts Interpretation Act 1901, para 23 (b).

5          Maximum quantity or number of units

(1)        For paragraph 85A (2) (a) of the Act, the maximum quantity or number of units of a pharmaceutical benefit mentioned in an item of Schedule 1 that an authorised optometrist may, in 1 prescription, direct to be supplied on any 1 occasion, either for all purposes or for a particular purpose (if any) mentioned in the item, is the quantity or number of units mentioned in the item.

(2)        For this section, the maximum quantity of a pharmaceutical benefit mentioned in an item in Schedule 1 is in the form mentioned in the description of the pharmaceutical benefit in the item.

Note   A pharmaceutical benefit may or may not have a pharmaceutical item. The description of a pharmaceutical benefit in an individual item of Schedule 1 makes it clear whether the item relates to a pharmaceutical benefit that has a pharmaceutical item or not.

6          Maximum number of repeats

For paragraph 85A (2) (b) of the Act, the maximum number of occasions for which an authorised optometrist may, in 1 prescription, direct that the supply of a pharmaceutical benefit mentioned in an item of Schedule 1 be repeated, either for all purposes or for a particular purpose (if any) mentioned in the item, is the number mentioned in the item.

7          Manner of administration

For paragraph 85A (2) (c) of the Act, the manner of administration of a pharmaceutical benefit mentioned in an item of Schedule 1 that an authorised optometrist may, in a prescription, direct to be used is the manner of administration mentioned in the description of the pharmaceutical benefit in the item.

8          Pharmaceutical benefits that may be prescribed by authorised optometrists

For subsection 88 (1C) of the Act, an authorised optometrist is authorised to write a prescription for the supply of a pharmaceutical benefit that is mentioned in Schedule 1.

9          Particular purpose of supply of a pharmaceutical benefit

For sections 4 and 5, if there are any particular purposes for which the supply of a pharmaceutical benefit may be directed:

(a)     those purposes are identified by the purpose code in the item of Schedule 1 dealing with the particular pharmaceutical benefit; and

(b)     the purpose that the purpose code stands for is set out in the lower part of the item.

SCHEDULE 1   MATTERS RELATING TO THE WRITING OF PRESCRIPTIONS FOR PHARMACEUTICAL BENEFITS BY AUTHORISED OPTOMETRISTS    (sections 3 to 7)
Pharmaceutical Benefit				Purposes of Supply
Listed drug	Form	Manner of administration	Brand	For all purposes (other than a particular purpose)		For particular purposes (purpose code followed by quantity or number)
				Maximum quantity or number	Maximum repeats	Maximum quantity or number	Maximum repeats
Aciclovir	Eye ointment 30 mg per g, 4.5 g	Application to the eye	Zovirax	1	..
Betaxolol	Eye drops, suspension, 2.5 mg (as hydrochloride) per mL, 5 mL	Application to the eye	Betoptic S	1	5
Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL	Application to the eye	Betoptic BetoQuin	1	5
Bimatoprost	Eye drops 300 micrograms per mL, 3 mL	Application to the eye	Lumigan	1	5
Bimatoprost with timolol	Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL	Application to the eye	Ganfort 0.3/5	1	5
Brimonidine	Eye drops containing brimonidine tartrate 1.5 mg per mL, 5 mL	Application to the eye	Alphagan P 1.5	1	5
Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL	Application to the eye	Alphagan Enidin	1	5
Brimonidine with Timolol	Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg (as maleate) per mL, 5 mL	Application to the eye	Combigan	1	5
Brinzolamide	Eye drops 10 mg per mL, 5 mL	Application to the eye	Azopt BrinzoQuin	1	5
Brinzolamide with Timolol	Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL	Application to the eye	Azarga	1	5
Carbomer	Eye gel 2 mg per g, 10 g	Application to the eye	GelTears PAA Viscotears	1	5
Eye gel 2 mg per g, single dose units 0.6 mL, 30	Application to the eye	Viscotears	3	5
Carbomer 974	Ocular lubricating gel 3 mg per g, single dose units 0.5 g, 30	Application to the eye	Poly Gel	3	5
Carmellose	Eye drops containing carmellose sodium 5 mg per mL, 15 mL	Application to the eye	Refresh Tears Plus	1	5
Eye drops containing carmellose sodium 10 mg per mL, 15 mL	Application to the eye	Refresh Liquigel	1	5
Eye drops containing carmellose sodium 2.5 mg per mL, single dose units 0.6 mL, 24	Application to the eye	TheraTears	4	5
Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 30	Application to the eye	Cellufresh	3	5
SCHEDULE 1   MATTERS RELATING TO THE WRITING OF PRESCRIPTIONS FOR PHARMACEUTICAL BENEFITS BY AUTHORISED OPTOMETRISTS — continued    (sections 3 to 7)
Pharmaceutical Benefit				Purposes of Supply
Listed drug	Form	Manner of administration	Brand	For all purposes (other than a particular purpose)		For particular purposes (purpose code followed by quantity or number)
				Maximum quantity or number	Maximum repeats	Maximum quantity or number	Maximum repeats
Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 30	Application to the eye	Celluvisc	3	5
Ocular lubricating gel containing carmellose sodium 10 mg per mL, single dose units 0.6 mL, 28	Application to the eye	TheraTears	3	5
Carmellose with glycerin	Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL	Application to the eye	Optive	1	3
Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, single dose units 0.4 mL, 30	Application to the eye	Optive	3	5
Chloramphenicol	Eye drops 5 mg per mL, 10 mL	Application to the eye	Chloromycetin Chlorsig	1	2
Eye ointment 10 mg per g, 4 g	Application to the eye	Chloromycetin Chlorsig	1	..
Cromoglycic Acid	Eye drops containing sodium cromoglycate 20 mg per mL, 10 mL	Application to the eye	Cromolux Opticrom	1	5
Dorzolamide	Eye drops 20 mg (as hydrochloride) per mL, 5 mL	Application to the eye	Trusopt	1	5
Dorzolamide with Timolol	Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL	Application to the eye	Cosopt	1	5
Fluorometholone	Eye drops 1 mg per mL, 5 mL	Application to the eye	Flucon FML Liquifilm	1	..
Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL	Application to the eye	Flarex	1	..
Flurbiprofen	Eye drops containing flurbiprofen sodium 300 micrograms per mL, single dose units 0.4 mL, 5	Application to the eye	Ocufen	1	..
Framycetin	Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL	Application to the eye/ear	Soframycin	1	2
Hydrocortisone	Eye ointment containing hydrocortisone acetate 5 mg per g, 5 g	Application to the eye	Hycor	1	..
Eye ointment containing hydrocortisone acetate 10 mg per g, 5 g	Application to the eye	Hycor	1	..
Hypromellose	Eye drops 3 mg per mL, 15 mL	Application to the eye	Genteal In a Wink Moisturising	1	5
Eye drops 5 mg per mL, 15 mL	Application to the eye	Methopt	1	5
Hypromellose with Carbomer 980	Ocular lubricating gel 3 mg-2 mg per g, 10 g	Application to the eye	Genteal gel HPMC PAA	1	5
Hypromellose with Dextran	Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL	Application to the eye	Poly-Tears Tears Naturale	1	5
Eye drops containing 3 mg hypromellose 2900 with 1 mg dextran 70 per mL, single dose units 0.4 mL, 28	Application to the eye	Bion Tears	3	5
Latanoprost	Eye drops 50 micrograms per mL, 2.5 mL	Application to the eye	Xalatan	1	5
Latanoprost with Timolol	Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL	Application to the eye	Xalacom	1	5
Paraffin	Eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g	Application to the eye	Duratears Poly Visc	2	5
Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g	Application to the eye	Ircal Lacri-Lube Poly Visc	1	5
Pilocarpine	Eye drops containing pilocarpine hydrochloride 10 mg per mL, 15 mL	Application to the eye	Isopto Carpine	1	5
Eye drops containing pilocarpine hydrochloride 20 mg per mL, 15 mL	Application to the eye	Isopto Carpine	1	5
Eye drops containing pilocarpine hydrochloride 40 mg per mL, 15 mL	Application to the eye	Isopto Carpine	1	5
Polyethylene glycol 400	Eye drops 2.5 mg per mL, 15 mL	Application to the eye	Blink Intensive Tears	1	5
Eye drops 2.5 mg per mL, single dose units 0.4 mL, 20	Application to the eye	Blink Intensive Tears	5	5
Polyethylene Glycol 400 with Propylene Glycol	Eye drops 4 mg-3 mg per mL, 15 mL	Application to the eye	Systane	1	5
Eye drops 4 mg-3 mg per mL, single dose units 0.8 mL, 28	Application to the eye	Systane	2	5
Polyvinyl Alcohol	Eye drops 14 mg per mL, 15 mL	Application to the eye	Liquifilm Tears PVA Tears	1	5
Eye drops 14 mg per mL, 15 mL (contains sodium chlorite/hydrogen peroxide as preservative)	Application to the eye	Vistil	1	5
Eye drops 30 mg per mL, 15 mL	Application to the eye	Liquifilm Forte PVA Forte	1	5
Eye drops 30 mg per mL, 15 mL (contains sodium chlorite/hydrogen peroxide as preservative)	Application to the eye	Vistil Forte	1	5
Soy lecithin	Eye spray 10 mg per mL, 10 mL	Application	tearsagain	2	5
Sulfacetamide	Eye drops containing sulfacetamide sodium 100 mg per mL, 15 mL	Application to the eye	Bleph 10	1	2
Timolol	Eye drops 2.5 mg (as maleate) per mL, 5 mL	Application to the eye	Tenopt Timoptol	1	5
Eye drops 5 mg (as maleate) per mL, 5 mL	Application to the eye	Tenopt Timoptol	1	5
Eye drops (gellan gum solution) 2.5 mg (as maleate) per mL, 2.5 mL	Application to the eye	Timoptol XE	1	5
Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL	Application to the eye	Timoptol XE	1	5
Eye gel 1 mg (as maleate) per g, 5 g	Application to the eye	Nyogel	1	5
Travoprost	Eye drops 40 micrograms per mL, 2.5 mL	Application to the eye	Travatan	1	5
Travoprost with Timolol	Eye drops 40 micrograms travoprost with timolol 5 mg (as maleate) per mL, 2.5 mL	Application to the eye	Duotrav	1	5

Notes to the Determination — Prescription of pharmaceutical benefits by authorised optometrists
(PB 11 of 2009)

Note 1

The Determination — Prescription of pharmaceutical benefits by authorised optometrists (PB 11 of 2009) (in force under subsections 85A(1) and (2) and 88(1C) of the National Health Act 1953) as shown in this compilation is amended as indicated in the Tables below.

Table of Instruments

Title	Date of FRLI Registration	Date of commencement	Application, saving or transitional provisions
PB 11 of 2009	12 Feb 2009 (see F2009L00427)	1 Mar 2009
PB 27 of 2009	20 Mar 2009 (see F2009L01118)	1 Apr 2009	—
PB 52 of 2009	11 June 2009 (see F2009L02292)	1 July 2009	—
PB 67 of 2009	10 July 2009 (see F2009L02716)	1 Aug 2009	—
PB 111 of 2009	20 Nov 2009 (see F2009L04285)	1 Dec 2009	—
PB 19 of 2010	17 Mar 2010 (see F2010L00677)	1 Apr 2010	—
PB 37 of 2010	15 Apr 2010 (see F2010L00939)	1 May 2010	—
PB 71 of 2010	16 July 2010 (see F2010L02064)	1 Aug 2010	—
PB 98 of 2010	29 Oct 2010 (see F2010L02857)	1 Nov 2010	—

Table of Amendments

ad. = added or inserted      am. = amended      rep. = repealed      rs. = repealed and substituted
Provision affected	How affected
Schedule 1
Schedule 1........................................	am. PB 27, 52, 67 and 111 of 2009; PB 19, 37, 71 and 98 of 2010